A survival prediction nomogram for liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy.

被引：1
|
作者：
Wang-Gillam, Andrea
Hubner, Richard
Mirakhur, Beloo
de Jong, Floris
Belanger, Bruce
Chen, Li-Tzong
机构：
[1] Washington Univ, Sch Med St Louis, St Louis, MO USA
[2] Christie NHS Fdn Trust, Manchester, Lancs, England
[3] Ipsen Biopharmaceut Inc, Basking Ridge, NJ USA
[4] Shire GmbH, Zug, Switzerland
[5] Ipsen Biosci Inc, Cambridge, MA USA
[6] Natl Inst Canc Res, Natl Hlth Res Inst, Tainan, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e16204
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16204
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Nomogram for predicting overall survival (OS) in patients (pts) treated with liposomal irinotecan (nal-IRI) ± 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy in NAPOLI-1
    Wang-Gillam, Andrea
    Hubner, Richard
    Mirakhur, Beloo
    de Jong, Floris A.
    Belanger, Bruce
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [2] CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) 6 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
    Chen, L-T.
    Wang-Gillam, A.
    Shan, Y-S.
    Mercade, T. Macarulla
    Blanc, J. F.
    Hubner, R.
    Chiu, C-F.
    Schwartsmann, G.
    Siveke, J.
    Belanger, B.
    de Jong, F.
    Mamlouk, K.
    von Hoff, D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)±-5fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based (gem) therapy.
    Macarulla, Teresa Mercade
    Hubner, Richard
    Blanc, Jean-Frederic
    Wang-Gillam, Andrea
    Li, Chung-Pin
    Bodoky, Gyorgy
    Dean, Andrew Peter
    Yanshen, Shan
    Jameson, Gayle S.
    Lee, Kyung-Hun
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Braiteh, Fadi S.
    Cunningham, David
    Chen, Li-Tzong
    Von Hoff, Daniel D.
    Mamlouk, Khalid Kevin
    de Jong, Floris A.
    Siveke, Jens T.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [4] CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
    Chen Li-Tzong
    Andrea, Wang-Gillam
    Shan Yan-Shen
    Teresa, Macarulla
    Jean-Frederic, Blanc
    Richard, Hubner
    Chiu Chang-Fang
    Gilberto, Schwartsmann
    Jens, Siveke
    Marc, Pipas J.
    Bruce, Belanger
    Floris, de Jong
    Khalid, Mamlouk
    Daniel, Von Hoff
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] Efficacy and safety of liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received gemcitabine (gem)-based therapy: Post-hoc analysis of the NAPOLI-1 trial
    Chen, Li-Tzong
    Wang-Gillam, Andrea
    Yanshen, Shan
    Macarulla, Teresa
    Blanc, Jean-Frederic
    Hubner, Richard
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Siveke, Jens T.
    Pipas, J. Marc
    Belanger, Bruce
    de Jong, Floris
    Mamlouk, Khalid
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [6] Subgroup analysis by prior lines of metastatic therapy (mtx) in NAPOLI-1: A global, randomized phase 3 study of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV), vs. 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who have progressed following gemcitabine-based therapy.
    Bodoky
    Dean, Andrew Peter
    Yanshen, Shan
    Jameson, Gayle S.
    Lee, Kyung-Hun
    Blanc, Jean-Frederic
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Braiteh, Fadi S.
    Cunningham, David
    Chen, Li-Tzong
    Von Hoff, Daniel D.
    Mamlouk, Khalid Kevin
    Bhargava, Parul
    de Jong, Floris A.
    Hubner, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone
    Hubner, R. A.
    Chen, L-T.
    Li, C-P.
    Bodoky, G.
    Dean, A.
    Lee, K-H.
    Cunningham, D.
    Siveke, J. T.
    Braiteh, F. S.
    de Jong, F. A.
    Belanger, B.
    Walls, R.
    Mody, P. D.
    von Hoff, D. D.
    Wang-Gillam, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI-1: A phase III study of liposomal irinotecan (nal-IRI)±5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
    Siveke, Jens T.
    Hubner, Richard
    Macarulla, Teresa Mercade
    Wang-Gillam, Andrea
    Dean, Andrew Peter
    Blanc, Jean-Frederic
    Cunningham, David
    Mirakhur, Beloo
    Belanger, Bruce
    de Jong, Floris A.
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [9] The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV)
    Chen, L-T.
    Macarulla, T. M.
    Belanger, B.
    Mirakhur, B.
    de Jong, F. A.
    Siveke, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] Subgroup analysis by baseline pain intensity (BPI) and analgesic use (BAU) in NAPOLI-1: A phase III study of liposomal irinotecan (nal IRI)±5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
    Macarulla, Teresa Mercade
    Siveke, Jens T.
    Dean, Andrew Peter
    Hubner, Richard
    Blanc, Jean-Frederic
    Cunningham, David
    Chen, Li-Tzong
    Mirakhur, Beloo
    Chen, Jie
    de Jong, Floris A.
    Wang-Gillam, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345